Eastern Bank Buys 28,214 Shares of IQVIA Holdings Inc. $IQV

Eastern Bank grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 49.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,223 shares of the medical research company’s stock after purchasing an additional 28,214 shares during the quarter. Eastern Bank owned approximately 0.05% of IQVIA worth $16,187,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Verdence Capital Advisors LLC acquired a new stake in IQVIA in the 2nd quarter valued at approximately $3,612,000. Amundi boosted its position in shares of IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after acquiring an additional 405,250 shares during the period. Act Two Investors LLC acquired a new stake in shares of IQVIA in the second quarter worth $26,528,000. Diversified Trust Co increased its position in IQVIA by 57.2% during the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after acquiring an additional 15,487 shares during the period. Finally, Patton Fund Management Inc. acquired a new position in IQVIA during the 2nd quarter valued at $231,000. 89.62% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on IQV shares. Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. Stifel Nicolaus lifted their target price on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. BMO Capital Markets started coverage on IQVIA in a report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target for the company. Truist Financial raised their price objective on IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Evercore ISI boosted their price objective on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $249.19.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $241.95 on Wednesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The business’s fifty day moving average price is $225.53 and its two-hundred day moving average price is $201.95. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The stock has a market capitalization of $41.20 billion, a price-to-earnings ratio of 33.19, a price-to-earnings-growth ratio of 2.45 and a beta of 1.36.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.